BG
IOVA icon

Bollard Group’s Iovance Biotherapeutics IOVA Stock Holding History

Bollard Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,700
Closed -$18K – 283
2025
Q2 		$18K Hold
10,700
– – ﹤0.01% 249
2025
Q1 		$36K Hold
10,700
– – ﹤0.01% 226
2024
Q4 		$79K Hold
10,700
– – ﹤0.01% 201
2024
Q3 		$100K Hold
10,700
– – ﹤0.01% 205
2024
Q2 		$86K Buy
+10,700
New +$115K ﹤0.01% 203

Other funds holding IOVA

MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Bollard Group's IOVA Position: Q3 2025 in Review

Bollard Group sold out of Iovance Biotherapeutics (IOVA) in Q3 2025, closing a stake of 10,700 shares — an estimated $18K sold.

Bollard Group first reported a position in IOVA in Q2 2024 and held it in 5 quarters. The position peaked at $100K in Q3 2024. 253 funds tracked by Wall St. Rank hold IOVA as of Q3 2025.

  • Bollard Group reported no remaining Iovance Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Bollard Group sold 10,700 Iovance Biotherapeutics shares in Q3 2025, an estimated $18K.
  • Bollard Group first reported a position in Iovance Biotherapeutics in Q2 2024 and held it in 5 quarters.
  • Bollard Group's Iovance Biotherapeutics position peaked at $100K in Q3 2024.
  • 253 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2025.

Based on Bollard Group's 13F filing for Q3 2025, filed 14 Nov 2025.